InspireMD Director Reports Four Warrant Transactions

The warrant entries list $1.3827 for dispositions and $0.7674 for acquisitions; no Rule 10b5-1 plan is reported.

Available on EDGAR 09/23/2026 - 04:06 PM EDT Accepted by SEC EDGAR 09/23/2026 - 04:05 PM EDT

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

InspireMD, Inc. director Michael Berman reported indirect transactions dated September 18, 2026, involving Series J and Series K warrants tied to common stock. The Series J entries list a disposition and an acquisition of 30,625 warrants each, with exercise prices of $1.3827 and $0.7674, respectively. The Series K entries list a disposition and an acquisition of 61,248 warrants each, with the same respective exercise prices. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Other: 183,746 shares

Other 4 txns

Insider BERMAN MICHAEL

Role Director

Type	Security	Shares	Price	Value
Other	Series J Warrant (right to buy) ^{F1, F2, F3}	30,625	$0.00	$0.00
Other	Series J Warrant (right to buy) ^{F1, F4, F3}	30,625	$0.00	$0.00
Other	Series K Warrant (right to buy) ^{F5, F6, F3}	61,248	$0.00	$0.00
Other	Series K Warrant (right to buy) ^{F5, F7, F3}	61,248	$0.00	$0.00

Holdings After Transaction: Series J Warrant (right to buy) — 61,249 warrants (Indirect, See Footnote); Series K Warrant (right to buy) — 61,248 warrants (Indirect, See Footnote)

Footnotes (7)

F1. See Exhibit 99.1; Note 1
F2. See Exhibit 99.1; Note 2
F3. See Exhibit 99.1; Note 3
F4. See Exhibit 99.1; Note 4
F5. See Exhibit 99.1; Note 5
F6. See Exhibit 99.1; Note 6
F7. See Exhibit 99.1; Note 7

Key Figures

Series J warrants disposed: 30,625 warrants Series J warrants acquired: 30,625 warrants Series K warrants disposed: 61,248 warrants +3 more

6 metrics

Series J warrants disposed 30,625 warrants Transaction dated September 18, 2026

Series J warrants acquired 30,625 warrants Transaction dated September 18, 2026

Series K warrants disposed 61,248 warrants Transaction dated September 18, 2026

Series K warrants acquired 61,248 warrants Transaction dated September 18, 2026

Exercise price for warrant dispositions $1.3827 per share Series J and Series K transactions dated September 18, 2026

Exercise price for warrant acquisitions $0.7674 per share Series J and Series K transactions dated September 18, 2026

Key Terms

Series J Warrant (right to buy), Series K Warrant (right to buy), exercise price

3 terms

Series J Warrant (right to buy) financial

"Series J Warrant (right to buy)"

Series K Warrant (right to buy) financial

"Series K Warrant (right to buy)"

exercise price financial

"Series J warrant with exercise price $1.3827"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What warrant transactions did NSPR director Michael Berman report?

Michael Berman reported dispositions and acquisitions of Series J and Series K warrants dated September 18, 2026. Each Series J transaction involved 30,625 warrants, and each Series K transaction involved 61,248 warrants.

Were NSPR director Michael Berman's reported warrant transactions under a Rule 10b5-1 plan?

No Rule 10b5-1 plan is reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BERMAN MICHAEL

(Last)

(First)

(Middle)

C/O INSPIREMD, INC.

6303 WATERFORD DISTRICT DRIVE, SUITE 215

(Street)

MIAMI

FLORIDA

33126

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
InspireMD, Inc. [ NSPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Series J Warrant (right to buy)	$1.3827	09/18/2026		J⁽¹⁾			30,625	05/15/2023	⁽²⁾	Common Stock	30,625	$0	30,624	I⁽³⁾	See Footnote
Series J Warrant (right to buy)	$0.7674	09/18/2026		J⁽¹⁾		30,625		05/15/2023	⁽⁴⁾	Common Stock	30,625	$0	30,625	I⁽³⁾	See Footnote
Series K Warrant (right to buy)	$1.3827	09/18/2026		J⁽⁵⁾			61,248	05/15/2023	⁽⁶⁾	Common Stock	61,248	$0	0	I⁽³⁾	See Footnote
Series K Warrant (right to buy)	$0.7674	09/18/2026		J⁽⁵⁾		61,248		05/15/2023	⁽⁷⁾	Common Stock	61,248	$0	61,248	I⁽³⁾	See Footnote

Explanation of Responses:

1. See Exhibit 99.1; Note 1

2. See Exhibit 99.1; Note 2

3. See Exhibit 99.1; Note 3

4. See Exhibit 99.1; Note 4

5. See Exhibit 99.1; Note 5

6. See Exhibit 99.1; Note 6

7. See Exhibit 99.1; Note 7

	/s/ Michael Lawless, Attorney-in-Fact for Michael Berman	09/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR